Assessment of the Efficacy of Topical Curcumin in Treatment of Oral Lichen Planus

Shaymaa Hussein Rafat Kotb30 enrolled

Overview

to evaluate the therapeutic impact of curcumin as Alternative or Complementary to Triamcinolone Acetonate in Treatment of Oral Lichen Planus.

Background: Oral lichen planus (OLP) is a chronic inflammatory disorder affecting the mucous membranes, believed to be an immune-mediated condition. Its persisting nature can lead to extended discomfort for those affected. The primary symptoms are pain and a burning sensation, with a potential risk of malignancy if not properly managed, necessitating lifelong clinical monitoring. Presently, OLP is considered a significant challenge due to the absence of a definitive cure. Patients \& patients: Thirty patients with oral lichen planus were divided into three groups, 10 patients each: Group A: ten patients with OLP were received topical triamcinolone acetonide. Group B: ten patients with OLP were received topical curcumin. Group C: ten patients with oral lichen planus were received topical triamcinolone acetonide combiend with topical curcumin. For six weeks. Each patient was examined at baseline,1 and 3months of therapy. Pain was scored using the visual analogue scale. Salivary level of interleukin 1 were estimated at baseline,1and 3 months' evaluation periods.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Oral Lichen Planus

Interventions

topical triamcinolone acetonideDRUG

ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks

Topical CurcuminDRUG

Ten patients with OLP received topical curcumin four times per day for six weeks.

topical triamcinolone acetonide combiend with topical curcuminDRUG

Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical diagnosis of OLP Exclusion Criteria: * Any systemic autoimmune disease * Any current use of anticoagulant or antiplatelet agents (curcumin has inhibitory effects on platelet aggregations). * Any topical, local or systemic corticosteroids therapy during the past 3 months. * lichenoid reaction from medications. * Pregnant or lactation women. * smokers

Locations (1)

Al-Azhar university

Asyut, Ass, Egypt

Outcomes

Primary Outcomes

Assess Visual Analog Scale (VAS) of OLP lesion

Qualitative.P-value \>0.05: Non significant(NS); P-value \<0.05: Significant(S); P-value\< 0.01: highly significant(HS)

Time frame: baseline ,1 ,3 months

Assess Oral Disease Severity Score

Qualitative.P-value \>0.05: Non significant(NS); P-value \<0.05: Significant(S); P-value\< 0.01: highly significant(HS)

Time frame: at base line ,after 1,3 months

Secondary Outcomes

Biochemical analysis of salivary interlukin 6 level using (ELISA)

Quantity

Time frame: baseline ,1 ,3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.